No relocation candidates, only local candidates will be considered.
South San Francisco, California
Parvus Therapeutics is pioneering a novel class of disease-specific, non-immunosuppressive biologics called NavacimsTM that are designed to halt and potentially cure autoimmune disease and other inflammatory disorders by restoring immune tolerance.
The Navacim technology platform is generating a rich pipeline of therapeutic candidates to address a wide range of inflammatory diseases. Our most advanced programs target Type 1 Diabetes (T1D) and autoimmune liver diseases. POC and efficacy in animals has been established not only for these two programs but also for multiple sclerosis (MS) and inflammatory bowel disease (IBD). Drug candidates have also been identified for celiac disease with others in earlier stages of research. Parvus has entered into a worldwide collaboration and license agreement with Genentech covering three of these programs: autoimmune liver, IBD, and celiac. In support of our partnership, Parvus is expanding to on-board the additional resources necessary to advance these programs to the clinic.
Navacims are comprised of iron oxide nanoparticles coated with disease-relevant peptide-major histocompatibility complex (pMHCs) proteins. Navacims trigger significant reduction in disease-associated inflammation without effecting general immunity thru the induction and abundant systemic expansion of disease-specific type 1 regulatory T (TR1) cells resulting in profound and durable therapeutic efficacy as assessed in preclinical disease models.
Our commercial strategy for Navacims follows a mix of corporate partnering and equity financing to support Parvus sponsored internal R&D. We have completed the buildout and start-up of new office and laboratory facilities in South San Francisco. The Parvus management team combines decades of experience in start-ups and biopharma, with demonstrated success in commercializing drugs from concept to market. We are seeking extraordinary and ambitious individuals who share our drive and desire to transform medicine.
The Research Associate will covalently link recombinant pMHC proteins to nanoparticles (the resulting drug is referred to as a Navacim) and help define conjugation processes for drug substance manufacturing. Additionally, the Research Associate will work closely with Research and CMC colleagues for the production and characterization of Navacims to support in vitro/in vivo efficacy and safety studies.
Compensation and title will be commensurate with experience level.
Responsibilities and duties include:
- Develop robust, scalable conjugation processes for production of Navacims
- Identify, define, and implement processes for optimization of Navacims
- Support conjugation and purification of research materials for in vitro/in vivo efficacy and safety studies
- Analytical characterization of pMHCs and Navacims
- Optimize lead candidate conjugates for scale-up and transfer to CMOs as appropriate
- Participate in all aspects of laboratory operation and organization including instrument maintenance, ordering, scheduling, and inventory
- Document experiments according to company protocols
- Present data internally as needed
- Work with CMC and across Parvus Development in the planning and coordination of CMC activities
- Comply with employee and environmental safety company guidelines
- A Bachelor’s or Master’s degree in biochemistry, chemistry, life sciences, or equivalent with 2+ years of relevant experience
- Experience with a variety of analytical methods including UV-Vis spectrophotometry, SDS-PAGE, and HPLC (SEC, RPLC, IEX, HIC
- Hands-on experience with protein reduction and conjugation techniques
- Experience with characterization of proteins and protein conjugates
- Experimental design and data analysis capabilities including Design of Experiments (DOE) is highly desirable
- Organized and detail oriented, possessing excellent record-keeping skills
- Able to work in a fast-paced environment, prioritize work, and adapt quickly to shifting project needs
- Collaborative attitude and strong team player, capable of working well within the CMC team and with other cross-functional groups